secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0000950170-25-034175
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed reports $273.7M cash, advances MM120 Phase 3 trials in GAD and MDD
--------------------------------------------------------------------------

- Cash and equivalents $273.7M at Dec 31, 2024 vs $99.7M a year ago; raised ~$250M in 2024.
- Q4 2024 R&D expense $21.8M (from $11.5M); full-year $65.3M (from $52.1M).
- Phase 3 Voyage (GAD) dosing initiated; topline data expected 1H 2026.
- Phase 3 Panorama (GAD) initiated Q1 2025; data expected 2H 2026.
- On track to start Phase 3 Emerge (MDD) 1H 2025; topline data 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017025034175/0000950170-25-034175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017025034175/mnmd-20250306.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-034175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer